Elizabeth Tsui; Karen L. Reckamp, MD, MS


Authored Items

Expanding Options for EGFR-Mutant Non–Small Cell Lung Cancer with Afatinib

June 2015, Vol 4, No 3 - Lung Cancer

Targeted treatments have proved to be clinically successful and represent the realization of personalized medicine’s potential. In non–small cell lung cancer (NSCLC), molecularly targeted treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib have shown dramatic responses in patients with activating mutations.1-3 EGFR [ Read More ]

Sign me up!